Zou Zuowei, Xia Luhua, Tang Saikang, Lin Lin, Wu Quanyang, Hou Donghui, Zhao Shijun
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Department of Nuclear Medicine Tumor Hospital Affiliated to Xinjiang Medical University Urumqi Xinjiang China.
Cancer Innov. 2025 Jun 2;4(4):e70015. doi: 10.1002/cai2.70015. eCollection 2025 Aug.
Ovarian cancer patients with elevated serum CA125 levels after operation have a high incidence of relapse or metastasis. F-FDG PET/CT is an effective imaging method for identifying recurrent or metastatic lesions. This study systematically investigated the diagnostic value of F-FDG PET/CT in this patient population.
A systematic search of PubMed, Embase, Cochrane Library (Central), Web of Science (SCI-Expanded), and Chinese databases (CNKI, VIP database, Wan Fang Data, CBM) was performed. Studies that evaluated the diagnostic value of F-FDG PET/CT for relapse or dissemination in postoperative ovarian cancer patients with elevated serum CA125 levels were included. The methodological quality of the studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Data were analyzed for heterogeneity using Meta-Disc 1.4 software. Sensitivity analysis and release bias evaluation were conducted using STATA 14.0 software.Thirteen studies (including 421 female patients) qualified for the meta-analysis. The pooled sensitivity and specificity of F-FDG PET/CT were 0.94 (95% CI: 0.91-0.97) and 0.83 (95% CI: 0.71-0.91), respectively. The pooled positive likelihood proportion was 4.59 (95% CI: 2.81-7.51), the pooled negative likelihood proportion was 0.09 (95% CI: 0.05-0.15), and the pooled diagnostic odds ratio was 64.22 (95% CI: 27.21-151.57). The area under the curve was 0.9379. A sensitivity analysis and publication bias test indicated that the outcomes were steady, and there was no reporting bias.
F-FDG PET/CT has high diagnostic veracity for identifying recurrence or metastasis in ovarian cancer cases with increased serum CA125 levels after surgery. It can accurately detect recurrent or metastatic lesions, providing valuable information for clinical decision-making.
术后血清CA125水平升高的卵巢癌患者复发或转移发生率较高。F-FDG PET/CT是识别复发或转移病灶的有效成像方法。本研究系统地调查了F-FDG PET/CT在该患者群体中的诊断价值。
对PubMed、Embase、Cochrane图书馆（核心库）、科学网（SCI扩展版）和中文数据库（中国知网、维普数据库、万方数据、中国生物医学文献数据库）进行系统检索。纳入评估F-FDG PET/CT对血清CA125水平升高的术后卵巢癌患者复发或播散的诊断价值的研究。使用诊断准确性研究质量评估2工具评估研究的方法学质量。使用Meta-Disc 1.4软件对数据进行异质性分析。使用STATA 14.0软件进行敏感性分析和发表偏倚评估。13项研究（包括421例女性患者）符合荟萃分析标准。F-FDG PET/CT的合并敏感性和特异性分别为0.94（95%CI：0.91-0.97）和0.83（95%CI：0.71-0.91）。合并阳性似然比为4.59（95%CI：2.81-7.51），合并阴性似然比为0.09（95%CI：0.05-0.15），合并诊断比值比为64.22（95%CI：27.21-151.57）。曲线下面积为0.9379。敏感性分析和发表偏倚检验表明结果稳定，且无报告偏倚。
F-FDG PET/CT对识别术后血清CA125水平升高的卵巢癌病例的复发或转移具有较高的诊断准确性。它可以准确检测复发或转移病灶，为临床决策提供有价值的信息。
